| 1.58 -0.03 (-1.86%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.1 | 1-year : | 2.45 |
| Resists | First : | 1.79 | Second : | 2.1 |
| Pivot price | 1.51  |
|||
| Supports | First : | 1.47 | Second : | 1.27 |
| MAs | MA(5) : | 1.56 |
MA(20) : | 1.48 |
| MA(100) : | 1.83 |
MA(250) : | 3.11 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.7 |
D(3) : | 69.6 |
| RSI | RSI(14): 51 |
|||
| 52-week | High : | 7.23 | Low : | 1.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AADI ] has closed below upper band by 30.5%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.67 - 1.68 | 1.68 - 1.68 |
| Low: | 1.56 - 1.56 | 1.56 - 1.57 |
| Close: | 1.57 - 1.58 | 1.58 - 1.59 |
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Fri, 26 Jul 2024
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Decline in Short Interest - Defense World
Mon, 15 Jul 2024
Small-Cap Sunday Highlights: Andean Precious Metals, Aadi Bioscience, Aprea Therapeutics, Arc Document Solutions, Curaleaf - The Dales Report
Wed, 03 Jul 2024
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop - Simply Wall St
Sat, 11 May 2024
Aadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Fri, 10 May 2024
Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI) - Simply Wall St
Thu, 09 May 2024
Aadi Bioscience First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 10.8 (%) |
| Held by Institutions | 54.1 (%) |
| Shares Short | 747 (K) |
| Shares Short P.Month | 890 (K) |
| EPS | -2.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.68 |
| Profit Margin | -288.8 % |
| Operating Margin | -364.6 % |
| Return on Assets (ttm) | -33.2 % |
| Return on Equity (ttm) | -58.3 % |
| Qtrly Rev. Growth | -8.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.97 |
| EBITDA (p.s.) | -3.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -58 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -0.62 |
| PEG Ratio | 0 |
| Price to Book value | 0.42 |
| Price to Sales | 1.62 |
| Price to Cash Flow | -0.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|